Sarepta Therapeutics Inc (SRPT)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 218,081 | 81,025 | 37,987 | -94,831 | -267,824 | -399,282 | -509,795 | -587,408 | -536,201 | -535,181 | -438,284 | -394,726 | -459,710 | -524,613 | -627,223 | -598,002 | -564,163 | -623,666 | -610,188 | -747,202 |
| Total assets | US$ in thousands | 3,963,170 | 3,599,930 | 3,424,260 | 3,224,380 | 3,264,580 | 3,109,710 | 3,125,890 | 3,059,790 | 3,128,370 | 3,156,150 | 2,996,850 | 3,056,150 | 3,147,970 | 2,662,220 | 2,759,070 | 2,765,230 | 2,984,720 | 2,780,660 | 2,883,040 | 2,947,390 |
| Operating ROA | 5.50% | 2.25% | 1.11% | -2.94% | -8.20% | -12.84% | -16.31% | -19.20% | -17.14% | -16.96% | -14.62% | -12.92% | -14.60% | -19.71% | -22.73% | -21.63% | -18.90% | -22.43% | -21.16% | -25.35% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $218,081K ÷ $3,963,170K
= 5.50%
Sarepta Therapeutics Inc's operating return on assets (operating ROA) has shown a fluctuating trend over the period from March 31, 2020, to December 31, 2024. The operating ROA started at a negative level, gradually improving through the quarters. The company struggled with negative operating ROA figures for several quarters, indicating challenges in generating operating income relative to its assets.
However, there was a notable turnaround starting from the last quarter of 2023, with the operating ROA shifting into positive territory. This positive trend continued into 2024, with a steady improvement in the operating ROA figures for each subsequent quarter.
The transition from negative to positive operating ROA suggests that Sarepta Therapeutics Inc has been able to enhance its operational efficiency and profitability, indicating a more effective utilization of its assets to generate operating income. This improvement reflects positively on the company's financial performance and may indicate better prospects for future profitability.
Peer comparison
Dec 31, 2024